Table II.
The association between ever or current postmenopausal hormone therapy use and breast cancer risk by FGFR2 rs1219648 genotype.
| Never use |
Ever use |
Estrogen use |
Estrogen+progestogen use |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | Controls | Cases | Odds ratio | Controls | Cases | Odds ratio | Controls | Cases | Odds ratio | Controls | Cases | Odds ratio |
| (N) | (N) | (95% CI) a | (N) | (N) | (95% CI) a | (N) | (N) | (95% CI) a | (N) | (N) | (95% CI) a | |
|
|
|
|
|
|||||||||
| AA | 132 | 110 | 1 (ref) | 161 | 153 | 1.05 (0.74-1.49) |
79 | 53 | 0.73 (0.47-1.14) |
77 | 94 | 1.31 (0.87-1.97) |
| AG | 171 | 184 | 1.28 (0.92-1.78) |
230 | 280 | 1.38 (1.01-1.90) |
110 | 111 | 1.10 (0.76-1.61) |
110 | 156 | 1.71 (1.18-2.48) |
| GG | 56 | 58 | 1.26 (0.81-1.98) |
55 | 82 | 1.68 (1.08-2.62) |
26 | 44 | 1.93 (1.11–3.36) |
29 | 34 | 1.25 (0.69-2.25) |
| p-interaction | 0.55 | 0.08 | 0.48 | |||||||||
| Never use |
Current use b |
Estrogen current use b |
Estrogen+progestogen current use b |
|||||||||
| Controls | Cases | Odds ratio | Controls | Cases | Odds ratio | Controls | Cases | Odds ratio | Controls | Cases | Odds ratio | |
| Genotype | (N) | (N) | (95% CI) a | (N) | (N) | (95% CI) a | (N) | (N) | (95% CI) a | (N) | (N) | (95% CI) a |
|
|
|
|
|
|||||||||
| AA | 132 | 110 | 1 (ref) | 137 | 141 | 1.16 (0.81-1.66) |
72 | 60 | 0.93 (0.60-1.46) |
66 | 87 | 1.43 (0.94-2.20) |
| AG | 171 | 184 | 1.28 (0.92-1.78) |
184 | 255 | 1.63 (1.17-2.26) |
93 | 114 | 1.35 (0.92-2.00) |
91 | 146 | 1.95 (1.33-2.86) |
| GG | 56 | 58 | 1.26 (0.81-1.98) |
48 | 72 | 1.69 (1.06-2.68) |
27 | 40 | 1.65 (0.94-2.90) |
24 | 32 | 1.45 (0.78-2.69) |
| p-interaction | 0.64 | 0.10 | 0.60 | |||||||||
a
Odds ratios adjusted for age and state of residence.
b
Current use category includes participants that reported using hormone therapy within the calendar year two years prior of the reference date. Abbreviation: CI, confidence interval; ref, reference category.